^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

Melanocortin receptor agonist

Related drugs:
3ms
Stress and the Nervous System (clinicaltrials.gov)
P=N/A, N=23, Completed, Brigham and Women's Hospital | Active, not recruiting --> Completed
Trial completion
9ms
Double mutation for multiple endocrine neoplasia associated with congenital adrenal hyperplasia. (PubMed, Endocrinol Diabetes Metab Case Rep)
A 39 year old female with signs of hyperandrogenism, was diagnosed with congenital adrenal hyperplasia after a cortrosyn test...Multiple endocrine neoplasia syndromes describe a group of heterogeneous diseases. Hyperparathyroidism is common among multiple endocrine neoplasia syndromes.
Journal
|
RET (Ret Proto-Oncogene)
1year
Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis (clinicaltrials.gov)
P=N/A, N=76, Completed, University of Virginia | Active, not recruiting --> Completed
Trial completion
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
over1year
Melanocortin Receptor Agonist Bremelanotide Induces Cell Death and Growth Inhibition in Glioblastoma Cells via Suppression of Survivin Expression. (PubMed, Anticancer Res)
The present results identified melanocortin receptors 3 and 4 as novel and viable therapeutic targets for glioblastoma. Activation of these receptors by bremelanotide may inhibit the expression of survivin, thereby sensitizing glioblastoma cells to cell death.
Journal
|
BIRC5 (Baculoviral IAP repeat containing 5)
|
Tagrisso (osimertinib) • temozolomide
2years
Defining the Mechanisms Underlying Adrenal Insufficiency in Cirrhosis (clinicaltrials.gov)
P=N/A, N=76, Active, not recruiting, University of Virginia | Not yet recruiting --> Active, not recruiting | N=135 --> 76 | Trial completion date: Dec 2023 --> Jun 2024 | Trial primary completion date: Dec 2022 --> Jun 2023
Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL10 (Interleukin 10)
over2years
Evaluation of the Effectiveness and Tolerance of Tetracosactide Synacthen® in the Treatment of Post Dural Puncture Headaches (ESYBRECHE) (clinicaltrials.gov)
P2, N=46, Terminated, Hospices Civils de Lyon | N=88 --> 46 | Trial completion date: Dec 2023 --> Nov 2022 | Recruiting --> Terminated; Interim analysis and decision of the independent committee, investigators and sponsor (futility) (2023/10/05)
Enrollment change • Trial completion date • Trial termination
over2years
Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS (clinicaltrials.gov)
P1, N=144, Recruiting, University of Virginia | Trial completion date: May 2024 --> May 2026 | Trial primary completion date: Apr 2024 --> Apr 2026
Trial completion date • Trial primary completion date
|
Ovidrel (choriogonadotropin alfa)
over2years
Evaluation of Adrenal Androgens in Normal and Obese Girls After Suppression and Stimulation (clinicaltrials.gov)
P=N/A, N=84, Active, not recruiting, University of Virginia | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
Enrollment closed • Trial completion date • Trial primary completion date
5years
11C-metomidate PET/CT detected multiple ectopic adrenal rest tumors in a woman with congenital adrenal hyperplasia. (PubMed, J Clin Endocrinol Metab)
Adrenal rest tumors can give rise to high androgen levels in spite of suppressive supraphysiological glucocorticoid doses. This case illustrates, for the first time, the value of 11C-metomidate PET as a sensitive method in documenting adrenal rest tumors, currently considered rare in women with CAH.
Clinical • Journal
|
CYP17A1 (Cytochrome P450 Family 17 Subfamily A Member 1)
|
prednisolone
5years
A computational drug repositioning method applied to rare diseases: Adrenocortical carcinoma. (PubMed, Sci Rep)
When results are analyzed using all available information, a number of novel predicted associations related to ACC appear to be valid according to current knowledge. We expect the predicted relations will be useful for drug repositioning in ACC since the resulting ranked lists of drugs and protein targets can be used to expedite the necessary clinical processes.
Journal
|
TOP2A (DNA topoisomerase 2-alpha) • IGF1R (Insulin-like growth factor 1 receptor) • DHCR7 (7-Dehydrocholesterol Reductase)
over5years
[VIRTUAL] A Rare Case of Atypical Teratoid/Rhabdoid Tumor of Sellar Region in an Adult (ENDO-I 2020)
Cosyntropin stimulation test showed a 30-minute cortisol of 2.8 mcg/dL and a 60-minute cortisol of 4 mcg/dL...She was started on levothyroxine 88 mcg, DDAVP 0.1 mg PO twice daily and stress dose steroids which was weaned down to prednisone 7.5 mg daily eventually...This case represents a rare occurrence of ATRT and suggests the need for suspicion in case of rapidly growing pituitary mass with progressive panhypopititarism.
Clinical • Late-breaking abstract
|
SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4) • SMARCB1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1) • PAX5 (Paired Box 5) • NCAM1 (Neural cell adhesion molecule 1) • VIM (Vimentin) • PAX8 (Paired box 8)
|
prednisone